scholarly journals Heparin Derivative SST0001

2020 ◽  
Author(s):  
Keyword(s):  
Heparin Derivative

Heparin-Associated Thrombocytopenia Treatment with Low Molecular Weight Heparin

1986 ◽  
Vol 55 (01) ◽  
pp. 037-039 ◽  
Author(s):  
Jean-F Vitoux ◽  
Jean-F Mathieu ◽  
Martine Roncato ◽  
Jean-N Fiessinger ◽  
Martine Aiach
Keyword(s):  
Molecular Weight ◽  
Clinical Improvement ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight ◽  
Antithrombotic Activity ◽  
Heparin Derivative

SummaryEight patients with heparin associated thrombocytopenia (HAT) were treated by a low molecular weight heparin derivative (LMW). Biological and clinical improvement occurred in all patients. This efficiency confirms the antithrombotic activity of LMW and allows its use in patients with HAT.

Antimetastatic Effect of an Orally Active Heparin Derivative on Experimentally Induced Metastasis

2008 ◽  
Vol 14 (9) ◽  
pp. 2841-2849 ◽  
Author(s):  
Dong Yun Lee ◽  
Kyeongsoon Park ◽  
Sang Kyoon Kim ◽  
Rang-Woon Park ◽  
Ick Chan Kwon ◽  
...  
Keyword(s):  
Antimetastatic Effect ◽  
Orally Active ◽  
Heparin Derivative ◽  
Experimentally Induced

The attenuation of experimental lung metastasis by a bile acid acylated-heparin derivative

Biomaterials ◽  
2007 ◽  
Vol 28 (16) ◽  
pp. 2667-2676 ◽  
Author(s):  
Kyeongsoon Park ◽  
Seok Ki Lee ◽  
Dai Hyun Son ◽  
Soo Ah Park ◽  
Kwangmeyung Kim ◽  
...  
Keyword(s):  
Bile Acid ◽  
Lung Metastasis ◽  
Heparin Derivative

scholarly journals Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling in vitro, and prolongs survival of sickle cell mice under hypoxia

Haematologica ◽  
2021 ◽  
Author(s):  
Osheiza Abdulmalik ◽  
Noureldien H. E. Darwish ◽  
Vandhana Muralidharan-Chari ◽  
Maii Abu Taleb ◽  
Shaker A. Mousa
Keyword(s):  
Sickle Cell ◽  
Inflammatory Responses ◽  
Anticoagulant Activity ◽  
Single Point ◽  
Bleeding Complications ◽  
Single Point Mutation ◽  
Repeated Dosing ◽  
Heparin Derivative

Sickle cell disease (SCD) is an autosomal recessive genetic disease caused by a single point mutation, resulting in abnormal sickle hemoglobin (HbS). During hypoxia or dehydration, HbS polymerizes to form insoluble aggregates and induces sickling of red blood cells (RBCs). RBC sickling increases adhesiveness of RBCs to alter the rheological properties of the blood and triggers inflammatory responses, leading to hemolysis and vaso-occlusive crisis sequelae. Unfractionated heparin (UFH) and low-molecular weight heparins (LMWH) have been suggested as treatments to relieve coagulation complications in SCD. However, they are associated with bleeding complications after repeated dosing. An alternative sulfated nonanticoagulant heparin derivative (S-NACH) was previously reported to have none to low systemic anticoagulant activity and no bleeding side effects, and it interfered with P-selectindependent binding of sickle cells to endothelial cells, with concomitant decrease in the levels of adhesion biomarkers in SCD mice. S-NACH has been further engineered and structurally enhanced to bind with and modify HbS to directly inhibit sickling, thus employing a multimodal approach. Here, we show that S-NACH can (i) directly engage in Schiff-base reactions with HbS to decrease RBC sickling under both normoxia and hypoxia in vitro, ii) prolong the survival of SCD mice under hypoxia, and (iii) regulate the altered steady state levels of pro- and antiinflammatory cytokines. Thus, our proof of concept in vitro and in vivo preclinical studies demonstrate that the multimodal S-NACH is a highly promising candidate for development into an improved and optimized alternative to LMWHs for the treatment of patients with SCD.

In vivo tumor targeting imaging of cyclic RGD-modified heparin derivative to αvβ3-integrin expressing tumor

2012 ◽  
Vol 42 (1) ◽  
pp. 9-14 ◽  
Author(s):  
Sung Eun Kim ◽  
Jungwook Chin ◽  
Hanna Lee ◽  
Youngro Byun ◽  
Kyeongsoon Park
Keyword(s):  
Tumor Targeting ◽  
Αvβ3 Integrin ◽  
Heparin Derivative

Abstract 3698: ODSH, a heparin derivative, enhances the efficacy of gemcitabine in a refractory human pancreatic tumor xenograft model

2012 ◽  
Author(s):  
Stephen G. Marcus ◽  
Pedro M. Quintana-Diez ◽  
Stephen Gately ◽  
Paul Gonzales ◽  
Bernardo Chavira ◽  
...  
Keyword(s):  
Pancreatic Tumor ◽  
Xenograft Model ◽  
Tumor Xenograft ◽  
Heparin Derivative

scholarly journals α-l-iduronate ring conformations in heparin and heparin derivatives. 13C Nuclear-magnetic-resonance analysis and titration data for variously desulphated and periodate-oxidized heparins

1978 ◽  
Vol 175 (1) ◽  
pp. 299-309 ◽  
Author(s):  
L A Fransson ◽  
T N Huckerby ◽  
I A Nieduszynski
Keyword(s):  
Periodate Oxidation ◽  
Nuclear Magnetic Resonance Analysis ◽  
Ring Conformation ◽  
Resonance Analysis ◽  
13C Nuclear Magnetic Resonance ◽  
Titration Data ◽  
Heparin Derivatives ◽  
Anomeric Carbon ◽  
Heparin Derivative ◽  
Ring Conformations

A heparin derivative that had been O/N-desulphated and re-N-acetylated was investigated by 13C n.m.r. spectroscopy and potentiometric titration. Three forms of uronic acid were observed, tentatively identified as beta-D-glucuronate, and two different forms of alpha-L-iduronate. A comparison of the n.m.r. spectra of heparin, an oligosaccharide (beta-D-glucuronate-2-acetamido-2-deoxy-alpha-D-glucose)n, and heparin that had been subjected to selective oxidation of beta-D-glucuronate, enabled the position of the anomeric carbon of the latter residue to be assigned [delta 102.9 (p.p.m.)]. Periodate oxidation of O/N-desulphated heparin destroyed in addition, approx. 40% of the alpha-L-iduronate content. The remainder of the alpha-L-iduronate residues displayed only one anomeric resonance, at delta 99.7 (p.p.m.). In another preparation, after sequential desulphation of heparin (N-desulphation, re-N-acetylation and O-desulphation) the anomeric resonance of the alpha-L-iduronate residue shifted downfield [from delta99.7 (p.p.m.) to delta 102.3]indicating a change in ring conformation. These data support the interpretation that the unsulphated alpha-L-iduronate residues may adopt two conformations. It was shown that the proportions of alpha-L-iduronate conformers are determined by the sequence of desulphation operations. Also minor components of heparin were assigned.

Tumor Endothelial Cell Targeted Cyclic RGD-modified Heparin Derivative: Inhibition of Angiogenesis and Tumor Growth

2008 ◽  
Vol 25 (12) ◽  
pp. 2786-2798 ◽  
Author(s):  
Kyeongsoon Park ◽  
Yoo-Shin Kim ◽  
Gee Young Lee ◽  
Rang-Woon Park ◽  
In-San Kim ◽  
...  
Keyword(s):  
Endothelial Cell ◽  
Tumor Growth ◽  
Tumor Endothelial Cell ◽  
Inhibition Of Angiogenesis ◽  
Heparin Derivative
Sign in / Sign up

Export Citation Format

Share Document